ReviewOncoTargets and therapy2014
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 127 citations in OpenAlex.
- Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.Gynecologic oncology · 2024Trial
- Harnessing the power of targeted metal nanocarriers mediated photodynamic and photothermal therapy.Nanomedicine (London, England) · 2026Review
- Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin - an approach for enhanced cancer therapy.RSC advances · 2025Article
- Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?International journal of molecular sciences · 2024Review
- Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins.Nature communications · 2024Article
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.International journal of molecular sciences · 2024Review
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Review
- Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.Clinical Medicine Insights. Oncology · 2023Review
- Multifunctional Nanoparticles as High-Efficient Targeted Hypericin System for Theranostic Melanoma.Polymers · 2022Article
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One.Journal of medicinal chemistry · 2022Review
- Electrochemical Cytosensor Based on a Gold Nanostar-Decorated Graphene Oxide Platform for Gastric Cancer Cell Detection.Sensors (Basel, Switzerland) · 2022Article
- Folic Acid-Modified Fluorescent-Magnetic Nanoparticles for Efficient Isolation and Identification of Circulating Tumor Cells in Ovarian Cancer.Biosensors · 2022Article
- Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.Current treatment options in oncology · 2022Review
- The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics.Journal of biomaterials applications · 2021Article
- Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha.Heliyon · 2021Article
- Raltitrexed-Modified Gold and Silver Nanoparticles for Targeted Cancer Therapy: Cytotoxicity Behavior In Vitro on A549 and HCT-116 Human Cancer Cells.Materials (Basel, Switzerland) · 2021Article
- Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy.Frontiers in cell and developmental biology · 2021Review
- Folate Modified Long Circulating Nano-Emulsion as a Promising Approach for Improving the Efficiency of Chemotherapy Drugs in Cancer Treatment.Pharmaceutical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses and survival. Research has recently focused on targeted therapies, which represent a new, promising therapeutic approach, aimed to maximize tumor kill and minimize toxicity. Besides antiangiogenetic agents and poly (ADP-ribose) polymerase inhibitors, the folate, with its membrane-bound receptor, is currently one of the most investigated alternatives. In particular, folate receptor (FR) has been shown to be frequently overexpressed on the surface of almost all epithelial ovarian cancers, making this receptor an excellent tumor-associated antigen. There are two basic strategies to targeting FRs with therapeutic intent: the first is based on anti-FR antibody (ie, farletuzumab) and the second is based on folate-chemotherapy conjugates (ie, vintafolide/etarfolatide). Both strategies have been investigated in Phase III clinical trials. The aim of this review is to analyze the research regarding the activity of these promising anti-FR agents in patients affected by ovarian cancer, including anti-FR antibodies and folate-chemotherapy conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.